Location History:
- Morfelden, DE (1978 - 1980)
- Morfelden-Walldorf, DE (1981)
Company Filing History:
Years Active: 1978-1981
Introduction
Norbert Schulmeyer, an innovative inventor based in Morfelden, Germany, has made significant contributions to the field of pharmaceuticals. With a total of three patents to his name, Schulmeyer has focused his research on advanced therapeutic compounds that demonstrate remarkable medicinal properties.
Latest Patents
Schulmeyer's latest patents are a testament to his expertise and creativity. His first patent concerns the treatment of ulcers with acylated aminoalkyl cyanoguanidines. This innovative approach involves preparing compounds that correspond to specific chemical formulas, aimed at enhancing the effectiveness of treatments aimed at ulcers.
The second patent highlights the production of 6-aryl-s-triazolo-(4,3-alpha)-pyrido-(2,3-f)-(1,4)-diazepines. These compounds, noted for their anticonvulsive properties, have a complex chemical structure that includes various functional groups capable of binding to multiple molecular targets. Each of these patents reflects Schulmeyer's commitment to advancing pharmaceutical science.
Career Highlights
Norbert Schulmeyer’s professional journey is marked by his work at Deutsche Gold- und Silber-Scheideanstalt Vormals Roessler. His dedication to innovation in drug development has led to the creation of novel compounds that not only address urgent medical needs but also provide alternatives to existing therapies.
Collaborations
Throughout his career, Schulmeyer has collaborated with esteemed colleagues, including Walter von Bebenburg and Vladimir Jakovlev. These partnerships have fostered a collaborative environment that drives creativity and progress in their shared field of expertise.
Conclusion
In conclusion, Norbert Schulmeyer stands out as a notable inventor whose patents have the potential to impact the pharmaceutical industry significantly. His work exemplifies the spirit of innovation and dedication required to advance medical science. With his continued commitment to research and development, Schulmeyer is sure to contribute further to the world of pharmaceuticals.